Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma

Mikiko Takikita1, Ran Xie, Joon-Yong Chung

  • 1Tissue Array Research Program, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

Insights

Membranous Her3 expression indicates a poor prognosis for head and neck squamous cell carcinoma (HNSCC) patients. This finding suggests Her3 as a potential target for new HNSCC therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Head and neck squamous cell carcinoma (HNSCC) is a lethal malignancy.
  • Identifying new therapeutic targets and early detection methods for HNSCC is crucial.
  • The prognostic relevance of Her2 and Her3 receptor overexpression in HNSCC is debated.

Purpose of the Study:

  • To investigate the prognostic significance of Her2 and Her3 expression in HNSCC.
  • To determine the relationship between Her2/Her3 protein levels and patient outcomes.
  • To evaluate Her3 as a potential therapeutic target in HNSCC.

Main Methods:

  • Analysis of Her2 and Her3 protein expression in 387 primary, 20 metastatic, and 17 recurrent HNSCC tissues using immunohistochemistry.
  • Tissue microarrays were employed for protein expression analysis.
  • Statistical analysis correlated protein expression with clinicopathological parameters and patient survival.

Main Results:

  • Her3 exhibited both cytoplasmic and membranous expression patterns; Her2 showed uniform membranous expression.
  • High membranous Her2 expression was observed in 26.9% of primary tumors.
  • Membranous Her3 overexpression was more prevalent in metastatic tissues (P = 0.003) and associated with worse overall survival (P = 0.027), acting as an independent prognostic factor (HR, 1.51; P = 0.040).

Conclusions:

  • Membranous Her3 expression is significantly linked to poor prognosis in HNSCC patients.
  • Her3 represents a potential molecular target for novel HNSCC therapies.
  • Further research into Her3-targeted treatments for HNSCC is warranted.